Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 5 for:    ZN-c5

A Food Effect Study With ZN-c5 in Healthy Post-Menopausal Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04561752
Recruitment Status : Completed
First Posted : September 24, 2020
Last Update Posted : December 23, 2020
Sponsor:
Information provided by (Responsible Party):
Zeno Alpha Inc.

Brief Summary:
This is a single-center, randomized, open-label, two-period, 2-way crossover food effect study to determine the comparative bioavailability of ZN-c5 under fed and fasting conditions, following single-dose administration of ZN-c5 capsules (150mg).

Condition or disease Intervention/treatment Phase
Healthy Drug: ZN-c5 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description: All participants will receive the same treatment but are randomized to one of two different treatment sequences in fed and fasted states.
Masking: None (Open Label)
Primary Purpose: Other
Official Title: A Randomized, Open-Label, 2-Way Crossover, Single-Dose Food Effect Study of ZN-c5 in Healthy Adult Post-Menopausal Female Subjects
Actual Study Start Date : November 2, 2020
Actual Primary Completion Date : December 11, 2020
Actual Study Completion Date : December 16, 2020

Arm Intervention/treatment
Experimental: Treatment Sequence A-B
Participants will take ZN-c5 (150mg), single dose, under fasted conditions, and a week later, will take the same drug under fed conditions to determine the comparative bioavailability of ZN-c5 under these conditions.
Drug: ZN-c5
ZN-c5 is the study drug.

Experimental: Treatment Sequence B-A
Participants will take ZN-c5 (150mg), single dose, under fed conditions, and a week later, will take the same drug under fasted conditions to determine the comparative bioavailability of ZN-c5 under these conditions.
Drug: ZN-c5
ZN-c5 is the study drug.




Primary Outcome Measures :
  1. AUC0-t [ Time Frame: Days 1-4 ]
    Area under the plasma concentration-time curve (AUC) from time zero to the last sampling time

  2. Cmax [ Time Frame: Days 1-4 ]
    Maximum concentration

  3. Tmax [ Time Frame: Days 1-4 ]
    Time to maximum concentration

  4. AUC0-infinity [ Time Frame: Days 1-4 ]
    Area under the plasma concentration-time curve (AUC) from time zero to infinity


Secondary Outcome Measures :
  1. Assess the incidence, frequency, and severity of treatment-emergent adverse events (TEAEs) [ Time Frame: Approximately 45 days ]
    Safety and tolerability of ZN-c5



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   45 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy female volunteers
  • Body mass index (BMI) between > or = 18.0 kg/m2 and < or = 29.9 kg/m2, and a body weight > or = 50kg and < or = 100kg at Screening
  • Non-smoker and must not have used any tobacco products within 2 months prior to Screening, or if a smoker must be currently (and for the last 2 months prior to screening) smoking < or = 2 cigarettes or equivalent per week. Current smokers must be willing to abstain from the use of tobacco and products containing nicotine from 14 days prior to administration of study drug and through the EOS visit.
  • No relevant dietary restrictions, and be willing to consume a high calorie, high fat breakfast and other standard meals provided during the domiciled periods of the study
  • Post-menopausal for > or = 24 months. Status will be confirmed through testing of follicle-stimulating hormone (FSH) levels > or = 40 IU/L at Screening. Participants that are post-menopausal for < or = 24 months are still potentially eligible, but will be required to have a negative serum pregnancy test result at Screening and negative urine pregnancy test result prior to study drug administration.

Exclusion Criteria:

  • Any condition likely to affect the participant's ability to consume the standard meal provided during the domiciled periods of the study, or any condition that may make it difficult for the patient to comply with the requirement for fasting during the study
  • Blood donation or significant blood loss within 60 days prior to the first study drug administration
  • Plasma donation within 7 days prior to the first study drug administration
  • Fever (body temperature > or = 38C) or symptomatic viral or bacterial infection or febrile illness within 2 weeks prior to Screening
  • Positive serum pregnancy test at Screening or urine pregnancy test prior to administration of study drug (for participants who are post-menopausal for < or = 24 months only)
  • Positive toxicology screening panel or alcohol breath test
  • History of substance abuse or dependency or history of recreational intravenous (IV) drug use over the last 5 years (by self-declaration)
  • Regular alcohol consumption within the 6 months prior to study drug administration, defined as > 21 alcohol units per week

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04561752


Locations
Layout table for location information
New Zealand
Site 1
Christchurch, New Zealand, 8011
Sponsors and Collaborators
Zeno Alpha Inc.
Investigators
Layout table for investigator information
Study Chair: Dimitris Voliotis Zeno Alpha Inc.
Layout table for additonal information
Responsible Party: Zeno Alpha Inc.
ClinicalTrials.gov Identifier: NCT04561752    
Other Study ID Numbers: ZN-c5-006
First Posted: September 24, 2020    Key Record Dates
Last Update Posted: December 23, 2020
Last Verified: December 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Zeno Alpha Inc.:
Randomized
Postmenopause
Female